A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
31/08/2021at 09:24

Pfizer goes head to head with Sanofi's multi-blockbuster with new study data

A new phase III study conducted by Pfizer comparing its drug abrocitinib with Sanofi best-seller Dupixent favors the former's medicine.
Pfizer aims for a big market with its drug abrocitinib. | Photo: ANGELA WEISS/AFP / AFP
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN

Although Sanofi has enjoyed a fine head start with its eczema treatment, Dupixent, the only currently approved biological medication, several companies are hot on the French pharmaceutical company's heels.

Danish dermatology group Leo Pharma is one competitor, while several large foreign players are also throwing their hats into the ring.

One of these is Pfizer, which has recently published data from a phase III study where its competitor to Dupixent came out on top.

"The results of our first comparative study for abrocitinib illustrate the medication's potential as a meaningful symptom treatment for patients, and expands the substantial data volume for the JADE development program," says Pfizer Chief Development Officer, Inflammation & Immunology Michael Corbo.

Clinical trials have shown abrocitinib as having statistically stronger effect on several clinical points of measurement than Dupixent -- including itching and symptomatic skin proportion.

On the other hand, a higher prevalence of side effects appeared among patients treated with 200mg of abrocitinib rather than 300m of Dupixent. Regarding serious side effects, similar data emerged from both patients groups.

Delayed with FDA

Abrocitinib is currently being evaluated by the US Food & Drug Administration, but several delays have arisen in connection with the medication class the treatment belongs to, Janus kinase inhibitors.

Initially, the FDA was meant to have responded in April. That was then delayed to July, and Pfizer has yet to reveal a new deadline.

Numerous drugs of the same type, including one of Pfizer's other medications, Xeljanz, are being thoroughly tested by the FDA due to, among other things, a post-commercialization study of the drug that showed potential signs of significant side effects.

Decisions concerning Eli Lilly's Olumiant and Incyte's ruxolitinib have also been affected by the FDA's extended investigations.

Ascendis ready for new hires after FDA approval

Sanofi gets positive results for eczema treatment – this time in young children 

Eli Lilly in big reshuffle: Sets up new units for neuroscience and immunology

Pfizer launches phase III trial with RSV candidate in September 

Related articles:

  • Photo: Kevin Grønnemann/MedWatch

    Ascendis ready for new hires after FDA approval

    For subscribers

  • Photo: CHARLES PLATIAU/Reuters / X00217

    Sanofi gets positive results for eczema treatment – this time in young children

    For subscribers

  • Photo: Mike Blake/REUTERS / X00030

    Eli Lilly in big reshuffle: Sets up new units for neuroscience and immunology

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
  • AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  • AGC Biologics breaks ground on USD 190m Danish factory

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Foto: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Foto: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Foto: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Foto: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Further reading

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Foto: Phillips-medisize
Medtech

US medtech group expands production in Denmark

In just a few years, Phillips-Medisize has doubled its staffing, and is now expanding its production facility in Danish town Struer to keep up with demand.

For subscribers

Foto: Euha/foto Rechnitz
Hearing health

New batch of hearing firm recommendations moves GN up, Demant and Sonova down

Jefferies takes stock of hearing aid industry, and comes up with a new string of recommendations.

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Principal Laboratory Technologist

  • Commercial Director

  • Lead Data Architect

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Application Manager

  • Head of International Sales

  • Sr. Director, Drug Safety Physician

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Senior Regulatory Affairs Professional

See all jobs

Jobs

  • Principal Laboratory Technologist

  • Commercial Director

  • Lead Data Architect

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Application Manager

  • Head of International Sales

  • Sr. Director, Drug Safety Physician

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Head of Regulatory Affairs Danmark

  • Senior Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge